What Patient Subset Will Novel Lung Cancer Treatments Work Best For?

Published on

Topics include: Treatments and Understanding

As the treatment landscape for lung cancer continues to evolve, will novel approaches apply to a wide subset of patients? Renowned expert Dr. Jeffrey Crawford explains what factors go into making treatment decisions for patients with a history of smoking and shares statistics on how this patient population is typically affected by the genetic mutations EGFR, ALK and PD-L1. Dr. Crawford also discusses why molecular testing is critical before starting therapy. 

This is a Patient Empowerment Network program produced by Patient Power. We thank Celgene and Pfizer for their support.

View more programs featuring and

Produced in association with

Transcript

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Andrew Schorr:

Related Programs

Tips for Lung Cancer Patients Navigating Their Treatment Journey

Lung cancer experts Dr. Edward Kim and Dr. Jeffrey Crawford share actionable insights to help guide patients through treatment decision making.

Published:

Expert Perspective: What Are Doctors Testing for in Lung Cancer Patients?

Lung cancer experts Dr. Edward Kim and Dr. Jeffrey Crawford discuss what is fundamentally necessary to learn about each condition before initiating treatment and how to test for it.

Published:

A Lung Cancer Roundtable: Takeaways From ASCO 2018

A panel of lung cancer experts weigh in on the latest research and treatment developments announced at ASCO 2018. Watch now to stay up-to-date with current lung cancer news and new generation medicines.

Published:

Advertisement
Join Our Community Register for Events Read Our Latest Blog
Advertisement

Page last updated on March 28, 2019